QIAGEN
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA...
Read More
Website
Headquarters
Venlo, Netherlands (corporate) Hilden Düsseldorf, Germany (operational) Maryland, United States(operational),
Company Size
6,000
-
NOV 13, 2024 | 7:00 AM
Each year, more than 134 million patients experience adverse drug events, causing 2.4 million deaths worldwide. What if there was a better way to develop and prescribe safer, more effective... -
SEP 12, 2024 | 8:00 AM
Neoantigens are among the newest promising targets for cancer treatment. Unlike tumor-associated antigens, neoantigens are produced only by tumor cells. These unique molecular markers are hi...
-
JUN 27, 2024 | 10:00 AM
Variant detection of multiple genes from a single tumor sample requires high-throughput molecular testing. To meet this demand, targeted next-generation sequencing (NGS) panels are useful in...
-
JAN 16, 2024 | 8:00 AM
The clinical interpretation of genetic testing results remains one of the most significant hurdles in effectively applying genomics in modern medicine. Errors in variant interpretation, whet...
-
DEC 07, 2023 | 8:00 AM
As the vast landscape of genetic oncology continues to expand, the ability to understand and utilize the full potential of this rich data becomes increasingly challenging. As a result, resea...
-
NOV 16, 2023 | 10:00 AM
Across various stages of the clinical oncology workflow, from panel design to genomic testing and molecular tumor boards, the identification and validation of actionable genomic alterations...
-
JUL 11, 2023 | 8:00 AM
Our understanding of cancer mechanisms, genetics and complexities continues to expand rapidly. Without a streamlined, standardized and easy to understand organizational system to keep track...
-
MAR 23, 2023 | 8:00 AM
Date: March 23, 2023 Time: 8:00am (PDT), 11:00am (EDT), 8:00pm (CEST) Across clinical oncology applications, from molecular testing to cancer research the ability to identify potentially act...
-
NOV 09, 2022 | 3:00 AM
Date: November 9, 2021 Time: 3:00am (PDT), 6:00am (EDT), 12:00pm (CEST) An increasing number of cervical cancer screening programs are converting from cytology to primary HPV-based organiz...
-
JUN 02, 2022 | 8:00 AM
Date: June 02, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Artificial intelligence (AI) is currently a buzzword across almost all scientific disciplines and has the potential to re...
-
APR 14, 2022 | 8:00 AM
Date: April 14, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Across oncology applications, from research to molecular testing and pharmaceutical development, the ability to identify...
-
MAR 24, 2022 | 8:00 AM
Date: March 24, 2022 Time: 8:00am (PST), 11:00am (EST), 4:00pm (GMT) Key to precision oncology is the development of expert databases that organize and standardize information on cancer-rel...
-
JAN 20, 2022 | 11:00 AM
Date: January 20, 2022 Time: 11:00am (PST), 2:00pm (EST), 8:00pm (CEST) The Human Gene Mutation Database (HGMD) is a one-of-a-kind resource containing data for hundreds of thousands of varia...
-
SEP 09, 2021 | 7:00 AM
Date: September 9, 2021 Time: 7:00am (PDT), 10:00am (EDT) Founded and maintained by the Institute of Medical Genetics at Cardiff University in 1996, HGMD attempts to collate all known, publi...
-
JUN 30, 2021 | 11:00 AM
Date: June 30, 2021 Time: 11:00am PDT As next-generation DNA sequencing technology continues to evolve and become further integrated into routine clinical testing, the need for efficient and...
-
DEC 15, 2020 | 2:00 PM
Date: December 15, 2020 Time: 5:00am (PST), 8:00am (EST), 2:00pm (CET) QIAGEN proudly presents Dr. Tanja Nikolova, a leading expert in the field of obstetrics with extensive experience in...
-
NOV 14, 2019 | 10:30 AM
Breast cancer is the most frequently occurring form of cancer in women. While 5-year survival rates for localized disease approach 99%, cases of advanced breast cancer have a much poorer pro...
-
NOV 14, 2019 | 9:00 AM
Applying machine learning methods to structured, expert-curated content from scientific literature is a powerful way to discover latent knowledge. Building on the QIAGEN Knowledge Base, we us...
-
OCT 10, 2019 | 12:00 PM
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
-
SEP 12, 2019 | 10:30 AM
The emergence and spread of antimicrobial-resistant (AMR) bacteria and resistance mechanisms pose a serious challenge to laboratories in both hospital clinical microbiology and public health...
-
SEP 11, 2019 | 10:30 AM
In contrast to other countries in Latin America, Peru had been notoriously spared by the global dissemination of carbapenem-resistant Klebsiella pneumoniae (CR-Kp) until recently. Isolated ca...
